Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT07811726 is registered in ClinicalTrials.gov with NexThera Co., Ltd. as lead sponsor.

NCT NCT07811726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)
Lead sponsor
NexThera Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
June 11, 2026
Completion date
March 31, 2028
Enrollment
66 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

wet age related macular degeneration